Fiduciary Alliance’s Seres Therapeutics MCRB Stock Holding History

Fiduciary Alliance’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12	Closed	-$1.11K	–	625
2023 Q2	$1.11K	Buy	+12	New	+$1.31K	﹤0.01%	851

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fiduciary Alliance's MCRB Position: Q3 2023 in Review

Fiduciary Alliance sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 12 shares — an estimated $1.11K sold.

Fiduciary Alliance first reported a position in MCRB in Q2 2023 and held it in 1 quarter. The position peaked at $1.11K in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

Fiduciary Alliance reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
Fiduciary Alliance sold 12 Seres Therapeutics shares in Q3 2023, an estimated $1.11K.
Fiduciary Alliance first reported a position in Seres Therapeutics in Q2 2023 and held it in 1 quarter.
Fiduciary Alliance's Seres Therapeutics position peaked at $1.11K in Q2 2023.
134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.